Author:
Butzner Michael,Aronitz Elise,Cameron Heather,Tantakoun Krista,Shreay Sanatan,Drudge Christopher
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–626.
2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2020;142(25):e558–631.
3. Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, Fujino N, Higo T, Isobe M, Kamiya C, et al. JCS/JHFS 2018 Guideline on the diagnosis and treatment of Cardiomyopathies. Circ J. 2021;85(9):1590–689.
4. Terasaka N, Spanopoulos D, Miyagoshi H, Kubo T, Kitaoka H. Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: a nationwide medical claims database study. J Cardiol. 2023;81(3):316–22.
5. Butzner M, Rowin E, Yakubu A, Seale J, Robertson LA, Sarocco P, Maron MS. Clinical characteristics and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy treated in a range of settings in the United States. J Clin Med. 2022;11(13):3898.